Author(s):
S. Sivaprasad, Ch. Sadakvali, V. Ravi Kumar, P.V. Murali Krishna, Shaik Mohammed Yusuf, A. Srikanth
Email(s):
sagiliprasad2003@gmail.com
DOI:
10.52711/0974-360X.2022.00514 
Address:
S. Sivaprasad1*, Ch. Sadakvali2, V. Ravi Kumar1, P.V. Murali Krishna1, Shaik Mohammed Yusuf 3, A. Srikanth4
1MNR College of Pharmacy, MNR Higher Education and Research Academy Campus, Fasalwadi (V), Sangareddy, Telangana, India, 502294.
2Mohammadiya Institute of Pharmacy, Khammam, Telangana.
3Department of Pharmacy, College of Health Sciences, Debre Tabor University, Ethiopia.
4Lovely Professional University, Punjab.
*Corresponding Author
Published In:
Volume - 15,
Issue - 7,
Year - 2022
ABSTRACT:
Tenofovir disproxyl fumerate (TDF) is widely used drug in anti HIV treatment. The main disadvantage with TDF is its low bioavailability. To overcome this problem TDF is formulated in to nanoparticles by using nanoprecipitation method. The formulated nanoparticles were in the range of 106.8nm to 516.4nm. The effect of PLGA and TPGS on the formulated nanoparticles were also studied. It is evident that the concentration of PLGA played an important role in the entrapment and drug loading capacity. On the basis of drug loaded and entrapment efficiency the F8 formulation was considered as optimized formulation. Different analytical techniques were used to determine the amount of drug present in the optimized formulation. The optimized formulation (F8) was subjected to different drug release kinetic models and its stability studies were also conducted in accordance with ICH guidelines.
Cite this article:
S. Sivaprasad, Ch. Sadakvali, V. Ravi Kumar, P.V. Murali Krishna, Shaik Mohammed Yusuf , A. Srikanth. Formulation and Characterization of Tenofovir Disproxyl Fumerate Nanoparticles prepared by Nanoprecipitation Method. Research Journal of Pharmacy and Technology. 2022; 15(7):3075-0. doi: 10.52711/0974-360X.2022.00514
Cite(Electronic):
S. Sivaprasad, Ch. Sadakvali, V. Ravi Kumar, P.V. Murali Krishna, Shaik Mohammed Yusuf , A. Srikanth. Formulation and Characterization of Tenofovir Disproxyl Fumerate Nanoparticles prepared by Nanoprecipitation Method. Research Journal of Pharmacy and Technology. 2022; 15(7):3075-0. doi: 10.52711/0974-360X.2022.00514 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-7-36
REFERENCES:
1. M. Naga Sujan, Amit B Patil, D, V. Gowda. A Review on Methods of Preparation and Characterisation of the solid Lipid Nanoparticles. Research J. Pharm. and Tech. 2020; 13(7): 3433-3441.
2. Gastaldi L, Battaglia L, Peira E, Chirio D, Muntoni E, Solazzi I. Solid lipid nanoparticles as vehicles of drugs to the brain: Current state of the art. Eur J Pharm Biopharm. 2014; 8(7): 433-444.
3. Manjunath Kopparam, Suresh V Kulkarni, Shivu SN. Development, Characterization and In vitro Evaluation of Donepezil solid Lipid Nanoparticles. Research J. Pharm. and Tech. 2020; 13(7): 3113- 3121.
4. Gayathri Kumararaja, Saneesha P N, Satheesh Kumar S, Shahana Parveen V V, Shaikh Fuzail Abdur Rahim, Shamna K V, Shamna P A, R Sundaraganapathy, R Gayathri. Development and Characterization of Silver nanoparticles (AgNPs) using Aqueous leaves broth of Artemisia vulgaris L., and its Anti-fungal activity. Research J. Pharm. and Tech. 2019; 12(10): 4822-4826.
5. Lee E, Smith D, Fanwick P, Byrn S. Characterization and Anisotropic Lattice expansion/Contraction of Polymorphs of Tenofovir Disoproxil Fumarate, Crystal Growth and Design. 2010; 10(5): 2314-2322.
6. Gomes E, Mussel W, Resende J, Fialho S, Barbosa J, Carignani E, Geppi M, Yoshida M. Characterization of Tenofovir Disoproxil Fumarate and Its Behavior under Heating, Crystal Growth and Design, 2015; 15(4):1915-1922.
7. Cetin M, Atila, A, Kadioglu Y. Formulation and In vitro Characterization of Eudragit® L100 and Eudragit® L100-PLGA Nanoparticles Containing Diclofenac Sodium. AAPS Pharm SciTech.2010; 11(3): 1250-1256.
8. D. Alukda, T. Sturgis, and B.-B. C. Youan, “Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention,” Journal of Pharmaceutical Sciences.2011; 100 (8): 3345– 3356.
9. M. Chidambaram, K. Krishnasamy. Modifications to the conventional nanoprecipitation technique: an approach to fabricate narrow sized polymeric nanoparticles. Advanced Pharmaceutical Bulletin. 2014; 4(2): 205–208.
10. Hitesh Jain, Rushi Panchal, Dilrose Pabla, Jaimini Patel, Mansi Khirwadkar. Magnetic Nanoparticles: As a Drug Targeting Carrier. Research J. Pharm. and Tech.2011; 4(7): 1040-1045.
11. M. Naga Sujan, Amit B Patil, D, V. Gowda. A Review on Methods of Preparation and Characterisation of the solid Lipid Nanoparticles. Research J. Pharm. and Tech. 2020; 13(7): 3433-3441.